SeaSpine Holdings Corporation (SPNE) Stock Analysis
DELISTED 2023
What happened to SeaSpine Holdings Corporation (SPNE) stock?
SeaSpine Holdings Corporation (SPNE) no longer trades on public markets. It was delisted in January 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SeaSpine Holdings Corporation (SPNE) trades at $9.54. SeaSpine Holdings Corporation focuses on designing, developing, and commercializing surgical solutions for spinal disorders. The company offers orthobiologics and spinal implant solutions to neurosurgeons and orthopedic spine surgeons. Sector: Healthcare.
Last analyzed: May 9, 2026Analyst Coverage for SPNE: SPNE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SPNE against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
SPNE: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →SeaSpine Holdings Corporation (SPNE) Healthcare & Pipeline Overview
SeaSpine Holdings Corporation, a medical technology company, specializes in surgical solutions for spinal disorders, offering orthobiologics and spinal implants. With a focus on innovation and comprehensive spinal care, SeaSpine serves neurosurgeons and orthopedic surgeons globally, addressing a critical need in the medical device market.
What Is the Investment Thesis for SPNE?
SeaSpine Holdings Corporation presents an investment opportunity within the medical device sector, specifically targeting the spinal disorder solutions market. Key value drivers include the company's comprehensive product portfolio of orthobiologics and spinal implants, which addresses a wide range of spinal conditions. With a gross margin of 59.9%, SeaSpine demonstrates strong potential for profitability as it scales its operations. Growth catalysts include expanding its market presence both in the United States and internationally, as well as continued innovation in surgical navigation systems and minimally invasive solutions. However, the company's negative profit margin of -28.4% indicates ongoing challenges in achieving profitability. Successful execution of its growth strategies and efficient cost management are critical for realizing its long-term potential.
Based on FMP financials and quantitative analysis
SPNE Key Highlights
SeaSpine Holdings Corporation specializes in surgical solutions for spinal disorders, focusing on orthobiologics and spinal implants.
- The company's product portfolio includes demineralized bone matrix (DBM), collagen ceramic matrices, and spinal implant solutions for fusion procedures.
- SeaSpine's solutions cater to neurosurgeons and orthopedic spine surgeons, addressing lumbar, thoracic, and cervical spine conditions.
- The company has a gross margin of 59.9%, indicating strong potential for profitability.
- SeaSpine operates both in the United States and internationally, establishing a global presence in the spinal surgery market.
Who Are SPNE's Competitors?
SPNE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MDT Medtronic plc | $92.88 | -1.33% | $119B | 77 |
| JNJ Johnson & Johnson | $267.37 | -2.21% | $644B | 90 |
| ABT Abbott Laboratories | $114.26 | -0.15% | $198B | 70 |
| SYK Stryker Corporation | $340.11 | +0.04% | $131B | 79 |
| BSX Boston Scientific Corporation | $52.01 | +3.05% | $77.3B | 80 |
| EW Edwards Lifesciences Corporation | $92.28 | +1.43% | $53.1B | 93 |
| DXCM DexCom, Inc. | $89.92 | +0.04% | $33.9B | 93 |
| STE STERIS plc | $236.91 | +1.95% | $24.0B | 85 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SPNE's Key Strengths?
Comprehensive product portfolio of orthobiologics and spinal implants.
- Innovative surgical navigation system.
- Strong relationships with neurosurgeons and orthopedic spine surgeons.
- Global presence in the spinal surgery market.
What Are SPNE's Weaknesses?
Negative profit margin.
- Relatively smaller market share compared to larger competitors.
- Dependence on product innovation and regulatory approvals.
- Limited brand recognition compared to established players.
What Could Drive SPNE Stock Higher?
Launch of new spinal implant products designed for minimally invasive surgery.
- Expansion of the sales and marketing team to increase market penetration.
- Continued investment in research and development to innovate new solutions.
- Strategic partnerships with healthcare providers to offer comprehensive solutions.
What Are the Key Risks for SPNE?
Negative return on equity (-22.5%) — the business is not currently generating profit on shareholder capital.
- Intense competition from larger medical device companies could impact market share.
- Pricing pressures from healthcare providers and payers may affect profitability.
- Regulatory changes and product recalls could disrupt operations.
- Economic downturns affecting healthcare spending could reduce demand.
What Are the Growth Opportunities for SPNE?
- Expanding Product Portfolio: SeaSpine has the opportunity to expand its product portfolio by developing and commercializing new spinal implants and orthobiologics. The global spinal implants and orthobiologics market is projected to reach $12.7 billion by 2028, driven by technological advancements and increasing demand for minimally invasive procedures. By investing in research and development, SeaSpine can introduce innovative solutions that address unmet clinical needs and capture a larger share of this growing market. This includes expanding its offerings in areas such as 3D-printed implants and regenerative medicine.
- Geographic Expansion: SeaSpine can drive growth by expanding its geographic presence, particularly in international markets. Emerging economies in Asia-Pacific and Latin America offer significant growth potential due to increasing healthcare spending and rising demand for advanced medical technologies. By establishing strategic partnerships and distribution networks, SeaSpine can penetrate these markets and increase its revenue streams. This expansion should be coupled with localized product offerings to meet the specific needs of different regions.
- Strategic Acquisitions: SeaSpine can pursue strategic acquisitions to expand its product portfolio, acquire new technologies, and enhance its market position. The medical device industry is characterized by consolidation, and acquisitions can provide access to complementary products, technologies, and customer bases. By targeting companies with innovative solutions in areas such as minimally invasive surgery and regenerative medicine, SeaSpine can accelerate its growth and strengthen its competitive advantage. Careful due diligence and integration planning are essential for successful acquisitions.
- Surgical Navigation Systems: SeaSpine can capitalize on the growing demand for surgical navigation systems by further developing and commercializing its image-guided surgical solutions. Surgical navigation systems enhance surgical precision, reduce operative time, and improve patient outcomes. The market for surgical navigation systems is projected to grow at a CAGR of 9.8% from 2021 to 2028, driven by increasing adoption of minimally invasive procedures and technological advancements. SeaSpine can differentiate itself by offering user-friendly and cost-effective navigation solutions.
- Partnerships with Healthcare Providers: SeaSpine can strengthen its relationships with healthcare providers by offering comprehensive solutions that address their specific needs. This includes providing training and education programs, offering customized implant solutions, and developing value-based care models. By becoming a trusted partner to healthcare providers, SeaSpine can increase its market share and drive long-term growth. This approach should focus on building strong relationships with key opinion leaders and participating in clinical research studies.
What Are SPNE's Competitive Advantages?
- Proprietary technology in orthobiologics and spinal implants.
- Strong relationships with neurosurgeons and orthopedic spine surgeons.
- Comprehensive product portfolio addressing a wide range of spinal disorders.
- Surgical navigation system enhances surgical precision and outcomes.
What Does SPNE Do?
SeaSpine Holdings Corporation, incorporated in 2015 and headquartered in Carlsbad, California, is a medical technology company dedicated to the design, development, and commercialization of surgical solutions for spinal disorders. The company provides a comprehensive portfolio of orthobiologics and spinal implant solutions, enabling neurosurgeons and orthopedic spine surgeons to perform fusion procedures across the lumbar, thoracic, and cervical spine. SeaSpine's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers, all designed to improve bone fusion rates in various orthopedic surgeries, including spine, hip, and extremities procedures. These products are available in multiple forms, such as fibers, putties, pastes, and strips, catering to diverse surgical needs. In addition to orthobiologics, SeaSpine offers a range of implant products focused on spinal decompression, alignment, and stabilization. These implants are complemented by image-guided surgical solutions, including a surgical navigation system, which facilitates fusion in degenerative, minimally invasive, and complex spinal deformity procedures. SeaSpine's solutions aim to enhance surgical precision and patient outcomes across different spinal regions. The company operates both in the United States and internationally, establishing a global presence in the spinal surgery market. SeaSpine continues to innovate and expand its product offerings to meet the evolving needs of spine surgeons and their patients.
What Products and Services Does SPNE Offer?
- Designs and develops surgical solutions for spinal disorders.
- Commercializes orthobiologics and spinal implant solutions.
- Offers products for fusion procedures in the lumbar, thoracic, and cervical spine.
- Provides demineralized bone matrix (DBM) and collagen ceramic matrices.
- Offers spinal implants for decompression, alignment, and stabilization.
- Provides image-guided surgical solutions and surgical navigation systems.
- Serves neurosurgeons and orthopedic spine surgeons.
How Does SPNE Make Money?
- Develops and manufactures orthobiologics and spinal implants.
- Sells products directly to hospitals and surgical centers.
- Generates revenue through product sales in the United States and internationally.
- Invests in research and development to innovate new solutions.
What Industry Does SPNE Operate In?
SeaSpine Holdings Corporation operates within the medical device industry, specifically targeting the spinal disorder solutions market. This market is characterized by continuous innovation in surgical techniques and implant technologies. The aging global population and increasing prevalence of spinal disorders drive demand for advanced spinal solutions. SeaSpine competes with larger medical device companies and specialized spinal implant manufacturers. The company's focus on orthobiologics and surgical navigation systems positions it to capitalize on the growing trend towards minimally invasive and personalized surgical approaches.
Who Are SPNE's Key Customers?
- Neurosurgeons
- Orthopedic spine surgeons
- Hospitals
- Surgical centers
Company Profile
SeaSpine Holdings Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Carlsbad, US. The company is led by CEO Keith C. Valentine. SPNE has traded publicly since 2015.
Key Financial Metrics
Return on equity for SeaSpine Holdings Corporation stands at -22.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -14.4%, showing how much profit it generates from its asset base. A current ratio of 1.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.0%, the inverse of the P/E and a quick read on earnings relative to price.
SPNE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying activity often signals confidence in the company's future prospects, suggesting those with the most knowledge believe the stock is undervalued.
- The social trading community seems to be buzzing with positive sentiment around SeaSpine's innovative product pipeline, hinting at potential market share gains.
- There's a growing perception that SeaSpine is well-positioned to capitalize on the aging population and increasing demand for spinal solutions, mirroring trends seen in similar healthcare companies.
- Positive community discussions suggest that SeaSpine's strategic partnerships and collaborations are viewed as a catalyst for future growth, similar to how key partnerships fueled growth for companies like Intuitive Surgical.
Bear Case
- Despite positive sentiment, some in the community are concerned about SeaSpine's ability to effectively scale production to meet anticipated demand, a challenge faced by many growing companies.
- There are whispers in the community about potential increased competition in the spinal solutions market, which could erode SeaSpine's market share and pricing power.
- Some bearish voices highlight the inherent risks associated with medical device companies, including potential product recalls or regulatory hurdles, reminiscent of challenges faced by other players in the healthcare sector.
- The community has expressed concerns about the overall economic climate and its potential impact on elective surgical procedures, which could negatively affect SeaSpine's revenue, similar to the slowdown experienced by medical device companies during economic downturns.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SPNE Latest News
No recent news available for SPNE.
Leadership: Keith C. Valentine
CEO
Keith C. Valentine serves as the Chief Executive Officer of SeaSpine Holdings Corporation. His career spans several leadership roles within the medical device industry, bringing extensive experience in strategic planning and execution. Prior to SeaSpine, Valentine held key positions at NuVasive, Inc., including President and Chief Operating Officer. His background includes a strong focus on sales, marketing, and product development, contributing to his deep understanding of the spinal surgery market. Valentine's expertise is instrumental in guiding SeaSpine's growth and innovation initiatives.
Track Record: Under Keith C. Valentine's leadership, SeaSpine has focused on expanding its product portfolio and market presence. Key achievements include the development and commercialization of innovative surgical navigation systems and the expansion of its orthobiologics offerings. Valentine has overseen strategic initiatives to drive revenue growth and improve operational efficiency. His leadership has been crucial in navigating the competitive landscape and positioning SeaSpine for long-term success. He manages 523 employees.
SPNE Healthcare Stock FAQ
What happened to SeaSpine Holdings Corporation (SPNE) stock?
SeaSpine Holdings Corporation (SPNE) no longer trades on public markets. It was delisted in January 2023. The figures below are historical and are not a current quote.
Can I still buy SPNE shares?
No. SPNE stopped trading on public markets in January 2023, so the shares are not available through a broker. Anything you see quoted for SPNE elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before SPNE stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to SeaSpine Holdings Corporation. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does SeaSpine Holdings Corporation do?
SeaSpine Holdings Corporation is a medical technology company focused on designing, developing, and commercializing surgical solutions for spinal disorders. The company offers a comprehensive portfolio of orthobiologics and spinal implant solutions, enabling neurosurgeons and orthopedic spine surgeons to perform fusion procedures across the lumbar, thoracic, and cervical spine.
What do analysts say about SPNE stock?
Analyst coverage of SeaSpine Holdings Corporation focuses on the company's growth potential within the spinal disorder solutions market. Key valuation metrics include revenue growth, gross margin, and potential for profitability. Analysts consider the company's innovative product portfolio, strategic partnerships, and geographic expansion as key growth drivers. However, the company's negative profit margin and competitive landscape are also considered.
What are the main risks for SPNE?
SeaSpine Holdings Corporation faces several risks, including intense competition from larger medical device companies, pricing pressures from healthcare providers and payers, and regulatory changes and product recalls. The company's reliance on product innovation and regulatory approvals also poses a risk. Economic downturns affecting healthcare spending could reduce demand for its products.
How does SeaSpine Holdings Corporation's orthobiologics portfolio compare to competitors?
SeaSpine Holdings Corporation's orthobiologics portfolio includes a range of demineralized bone matrix (DBM), collagen ceramic matrices, and synthetic bone void fillers. The company focuses on improving bone fusion rates in orthopedic surgeries, including spine, hip, and extremities procedures. Compared to competitors, SeaSpine aims to offer a comprehensive and innovative portfolio with various forms, such as fibers, putties, pastes, and strips.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided sources and may not reflect the most recent developments.